Primary Market Research (PMR)
Hear directly from the stakeholders shaping your therapy’s future.
Thelansis combines qualitative and quantitative primary research with epidemiology, market intelligence, and commercial expertise to turn stakeholder perspectives into decision-ready evidence.
Our dedicated Primary Market Research practice designs, fields, and analyzes research with physicians, KOLs, patients, caregivers, payers, and other healthcare stakeholders to answer the questions that matter across clinical development, commercialization, market access, and lifecycle strategy.
Data Quality & Response Validation
KOL Reach Accuracy
Actionable Insight Delivery
Why Thelansis PMR?
Primary research is more powerful when stakeholder evidence doesn’t sit in isolation.
Stakeholder perspectives become more actionable when connected to the broader market context. At Thelansis, PMR is informed by our experience across epidemiology, market intelligence, market sizing, and commercial strategy.
This enables us to connect what stakeholders say with what the market is doing and create a more complete evidence base for strategic decisions.
Understand stakeholder needs
Identify unmet needs, treatment drivers, barriers, preferences, perceptions, and decision criteria across physicians, patients, caregivers, and payers.
De-risk strategic decisions
Test concepts, messaging, positioning, value propositions, pricing, access strategies, and product assumptions before significant investments are made.
Explain market behavior
Go beyond what stakeholders do to understand why they prescribe, switch, adopt, delay, recommend, access, or discontinue therapies.
Identify what is changing
Track shifts in stakeholder sentiment, brand perceptions, treatment behavior, competitive dynamics, and market expectations over time.
Our PMR Capabilities
Transforming stakeholder perspectives into actionable insights to guide clinical development and commercial success.
Understanding the “why” behind clinical and commercial decisions
In-depth interviews (IDIs), KOL interviews, physician and patient advisory boards, focus groups, and ethnographic and patient-journey research uncover the reasoning, barriers, motivations, and unmet needs that quantitative data alone cannot explain.
AI-assisted transcription, thematic coding, and cross-interview synthesis accelerate turnaround, while interview guide design, moderation, and interpretation remain led by experienced research professionals.
Key methods include:
- In-depth interviews
- KOL and expert interviews
- Physician and patient advisory boards
- Focus groups
- Ethnographic research
- Patient-journey research
- Open-ended qualitative exploration
Measuring attitudes, behaviors, preferences, and market dynamics at scale
Physician and patient surveys, Awareness-Trial-Usage (ATU) studies, message and concept testing, conjoint and pricing/willingness-to-pay research, and segmentation studies quantify what qualitative research surfaces directionally.
AI-enabled workflows support survey scripting, data preparation, cleaning, visualization, and preliminary analysis, with sample design, statistical validation, interpretation, and strategic conclusions remaining expert-reviewed.
Key methods include:
- Physician and patient surveys
- ATU studies
- Message and concept testing
- Conjoint analysis
- Pricing and willingness-to-pay research
- Segmentation studies
- Prescribing and treatment behavior research
Structured engagement with the stakeholders who shape a therapy’s trajectory.
We design and moderate physician advisory boards, patient and caregiver panels, payer roundtables, and recurring stakeholder panels aligned to specific clinical development, commercial, or market access questions.
AI supports panel recruitment screening and session summarization, while facilitation, discussion design, stakeholder engagement, and output synthesis remain led by our senior researchers.
Key formats include:
- Physician advisory boards
- Patient and caregiver panels
- Payer roundtables
- KOL engagements
- Stakeholder panels
- Recurring tracking panels
Turning fielded evidence into clear, decision-ready insights
We integrate qualitative and quantitative findings into unified insight reports, strategic recommendations, forecasting inputs, and stakeholder-ready presentations.
Where relevant, PMR findings can be connected with Thelansis epidemiological, market-sizing, and market-intelligence datasets to provide a more complete view of the opportunity.
AI accelerates data visualization and first-draft synthesis, while final interpretation, contextualization, and strategic framing remain analyst-led.
What Do We Do
Thelansis designs and executes end-to-end primary market research to uncover the stakeholder insights driving your drug’s commercial success.
Across the 20+ therapeutic areas we work in, PMR needs differ by category — rare disease research often means recruiting small, hard-to-reach patient and physician populations, while high-volume chronic and specialty categories demand large-sample quantitative rigor and competitive benchmarking. That’s the gap Thelansis’s PMR practice is built to close, wherever your asset sits.
Key Deliverables
Our research translates complex stakeholder feedback and diverse market signals into clear, decision-ready intelligence for your brand. Key outputs include:
Market landscaping and unmet need reports
KOL and physician interview summaries
Patient/caregiver journey and burden-of-illness reports
ATU and message/concept testing reports
Payer research and pricing/access studies
Advisory board and panel session reports
Segmentation and conjoint analysis outputs
Integrated qual+quant insight decks
Tracking study dashboards (brand health, ATU)
Benefits of Partnering with Thelansis
Partnering with Thelansis provides the robust evidence and deep stakeholder insights needed to accelerate market access and guide strategic biopharmaceutical decisions. Our clients benefit from:
Therapeutic Depth
PMR expertise spans 20+ therapeutic areas — oncology, rare diseases, CNS, immunology
Epidemiology-grounded research
One point of accountability, start to finish: one team owns the model and the dossier
Integrated intelligence
PMR isn't isolated — it connects with epidemiology, market sizing, and strategy work
One team across research and intelligence
Our teams connect disease burden and market context with PMR evidence—fewer handoffs
AI-accelerated, expert-led
AI accelerates scripting, coding, and synthesis—researchers keep oversight of quality
Global market fluency
Cost-efficient delivery from India, US/EU client-facing presence, global market reach
Ready to hear directly from the stakeholders who’ll decide your therapy’s success?
From early development and launch planning to market access and lifecycle strategy, Thelansis helps life sciences teams gather, interpret, and apply the voice of physicians, patients, caregivers, payers, and other key stakeholders.